UBS Rates Nuvalent (NUVL) hold, $124 Price Target

UBS shifted its outlook on Nuvalent, Inc. to a hold rating on June 10, 2026, setting a price target of $124, a 0.61% upside from the current price.

By EarningsIQ Research Desk · Published Jun 14, 2026, 2:01 AM EDT · Updated Jun 15, 2026, 1:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

UBS rated Nuvalent, Inc. ($NUVL) "hold" with a $124 price target on June 10, 2026.

Since the rating, $NUVL is up 0.0% after 1 week and up 0.1% to date (from the $123.35 close on Jun 10, 2026).

NUVL Nuvalent, Inc.

$123.43 +22.40% year to date

Daily close · Jun 18, 2026

Key Points

UBS shifted its stance on Nuvalent, Inc. to a hold rating on June 10, 2026, alongside a $124 price target.
UBS's $124 price target implies 0.61% upside from Nuvalent, Inc.'s ($NUVL) current $123.25 share price.
Nuvalent stock trades near $123.25, sitting close to its 52-week peak of $123.99.
Bernstein later adjusted its view on June 24, 2026, setting a market perform rating and a $124 target.

Get $NUVL trade alerts by text

We text you when insiders, Congress or big funds trade $NUVL. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nuvalent, Inc. alert may contain errors. Disclosures

UBS Shifts Stance on Nuvalent Shares

UBS updated its outlook on Nuvalent, Inc. (NGM: NUVL) on June 10, 2026, moving the biotechnology firm to a hold rating with a price target of $124. Analyst David Dai pointed the firm toward a more cautious view as the clinical-stage drug developer advances its pipeline of targeted cancer treatments.

12-month forecast

$NUVL price target

Nuvalent, Inc. daily closes and this analyst's $124 target. Not advice.

Analysts Set New Price Targets

Following the UBS update, Bernstein adjusted its outlook on June 24, 2026. Bernstein moved the stock to a market perform rating while setting a price target of $124, which matched the earlier target from UBS. Across Wall Street, a total of nine analysts maintain opinions on the company, resulting in a consensus recommendation of hold and a mean price target of $124.

Stock Performance Near Peak Levels

Shares of Nuvalent trade around $123.25, sitting just beneath the 52-week high of $123.99. The equity has climbed from its 52-week low of $71.13, supported by steady interest in the biotech sector. Because the firm focuses entirely on early and mid-stage clinical testing without commercial product sales yet, it does not currently generate positive earnings per share, leaving it without a meaningful price-to-earnings ratio.

Inside the Pipeline at Nuvalent

Based in Cambridge, Massachusetts, Nuvalent builds precision therapies for patients facing difficult-to-treat cancers. Its main pipeline assets include Zidesamtinib for ROS1-positive tumors, Neladalkib for ALK-positive conditions, and NVL-330 for HER2-driven cancers. These candidates aim to tackle treatment resistance and brain metastases while avoiding off-target side effects.

What to Watch at Nuvalent, Inc.

Investors will track upcoming clinical trial updates and corporate disclosures from Nuvalent to gauge progress across its lead drug candidates. As analysts keep a steady eye on valuation and trial milestones, future updates will offer clearer signals on how the pipeline advances.